Skip to main content
Genenta Science S.p.A. logo

Genenta Science S.p.A. — Investor Relations & Filings

Ticker · GNTA ISIN · US36870W1009 LEI · 815600E860D130824E49 US Professional, scientific and technical activities
Open in API
Filings indexed 87 across all filing types
Latest filing 2026-05-29 M&A Activity
Country IT Italy
Listing US GNTA

About Genenta Science S.p.A.

https://www.genenta.com/

Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.

Recent filings

Filing Released Lang Actions
6-K
M&A Activity Classification · 87% confidence The document is a Form 6-K current report by a foreign private issuer disclosing an amendment to an Investment Agreement under which the company acquires the remaining 80.5% equity of A.T.C. S.r.l. through a share issuance and related corporate transaction terms. This is neither an earnings release nor an annual/interim report but an announcement of an acquisition transaction (M&A). Therefore, it falls under our M&A Activity category.
2026-05-29 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K (“Report of Foreign Private Issuer”) filed under the Securities Exchange Act of 1934, containing a notice of license termination event. It is under 5,000 characters and serves as a regulatory disclosure rather than the underlying full report or financial statements. This aligns with the “Regulatory Filings (RNS)” category.
2026-05-19 English
6-K - Genenta Science S.p.A. (0001838716) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Genenta Science S.p.A., with the SEC. It reports a binding offer to acquire majority ownership in an Italian aerospace and defense company, Sòphia High Tech. The document includes details of the offer, strategic expansion plans, and forward-looking statements. It is a current report on material events or corporate developments, not a full annual or quarterly financial report, audit report, or earnings release. The Form 6-K is used for reporting significant events by foreign private issuers and is classified under Regulatory Filings (RNS) as it does not fit into other specific categories like M&A filings (which are typically Form 425 or DEFM14A), nor is it a proxy, dividend, or capital change announcement. The document is about a corporate event disclosure and includes exhibits such as the binding offer and press release, consistent with Regulatory Filings.
2026-03-27 English
3 - Genenta Science S.p.A. (0001838716) (Issuer)
Director's Dealing
2026-03-18 English
3 - Genenta Science S.p.A. (0001838716) (Issuer)
Director's Dealing
2026-03-18 English
3 - Genenta Science S.p.A. (0001838716) (Issuer)
Director's Dealing
2026-03-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.